Best Genomics Companies in Austin, United States
The 31 best Genomics companies in Austin, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Everlywell.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Austin
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Everlywell 🦄 Provider of home-based diagnostic tests for the detection of various diseases | $330M | 69 mo ago | Funding Raised | 614 | Julia Cheek Founder & CEO | Top 500k | — | — |
| 2 | Aspira Women's Health Provider of diagnostic solution for ovarian malignancy in women 32Funding top 29%Tech top 46%Market bottom 46%Fin. health bottom 36% All 7 signals ▾Fundingtop 29% Techtop 46% Marketbottom 46% Fin. healthbottom 36% Growthbottom 35% Globalbottom 30% Newsbottom 21% Funding: Raised $96.7M across 8 rounds · 8 rounds over 16 yrs (0.5/yr) Tech: 36 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 32/100 | $97M | 13 mo ago | Public | 85 85 → 60 (-29%) | — | Top 10M | — | — |
| 3 | Embark Veterinary Proivder of DNA test kits for dogs that enable dog owners to provide better pet care | $94M | 63 mo ago | Series B | 141 | Amish Desai Chief Executive Officer | Top 500k | 20 patents Canine DNA testing for coat color, breed ancestry, and related genetic traits | — |
| 4 | Asuragen Molecular diagnostics and genetics company advancing precision medicine in oncology | $80M | 85 mo ago | Acquired | 114 114 → 101 (-11%) | — | Top 50M | 349 patents Detection and analysis of repeat expansions and miRNA biomarkers in nucleic acids. | — |
| 5 | Endocare Provider of cancer diagnostic and therapeutic instruments | $53M | 233 mo ago | Acquired | 120 | — | — | 193 patents Medical cryosurgical devices and cryogen delivery systems for tissue ablation | — |
| 6 | Ambion Provider of RNA extraction reagents and products | $10M | 199 mo ago | Early Stage | 300 | — | — | 95 patents RNA extraction, preservation, and purification technologies for molecular biology applications | — |
| 7 | PHDx Solution for detection of diseases in patients | $6M | 100 mo ago | Deadpooled | — | Jim Canfield CEO & President | — | — | — |
| 8 | Seralogix Streamlining preclinical research with innovative technology and solutions for enhanced results | $5M | 128 mo ago | Funding Raised | — | Kenneth Drake Founder/CEO | — | — | — |
| 9 | Wellnicity Provider of personalized supplement and diet recommendations based on biochemical analysis | $4M | 105 mo ago | Seed | 2 | — | — | — | — |
| 10 | Genprex Developer of therapeutics to treat cancer at molecular level | $3M | 75 mo ago | Public | 28 28 → 23 (-18%) | — | Top 10M | 12 patents Cancer gene therapy vectors targeting NPRL2, TUSC2/TUSC4, and ALK-driven tumors | — |
| 11 | AptamiR Therapeutics Developer of microRNA-targeted therapeutics to treat human obesity | $3M | 122 mo ago | Seed | — | Marc Thibonnier Founder | — | — | — |
| 12 | Arpeggi Develops solutions for genome sequencing services | $195K | 165 mo ago | Acqui-Hired | — | — | — | — | — |
| 13 | ViaGen Provider of animal genetic preservation and cloning services | $150K | 190 mo ago | Acqui-Hired | 28 | Blake Russell CEO | — | 7 patents Livestock reproductive biotech: cloning, embryo transfer, and high-throughput genomic ancestry analysis. | — |
Top 12 Genomics companies in Austin
#1
Public · Austin, Texas · founded 1993 · 85 employees$96.7Mraised▾
Provider of diagnostic solution for ovarian malignancy in women. It offers products OVA1 and OVERA to detect the risk of ovarian cancer for patients. It also offers its flagship product for the detection of risk heredity breast and ovary cancer; ASPiRA GenetiXSM testing which offers comprehensive genetic testing options with a gynecologic focus.
- Sep 2025Post IPO$3M
- Mar 2025Post IPO$1.4M
- Jun 2024Post IPO$1.9M
- Jul 2020Post IPO$11M
#2
Funding Raised · Austin, Texas · founded 2014 · 614 employees$330Mraised▾
Provider of home-based diagnostic tests for the detection of various diseases. The company offers diagnostic tests kits for monitoring health and wellness. Users can book tests for cardiovascular health, food sensitivity, women's fertility, and health, metabolism, inflammation, and many more. The prescription is provided by the doctors for the tests based on the state's regulation.
#3
Series B · Austin, Texas · founded 2015 · 141 employees$94.3Mraised▾
Provider of DNA test kits for dogs that enable dog owners to provide better pet care. The test tracks more than 200,000 genetic markers. The test analyzes the dog's ancestry and provides an overview of both genetic disease risk and heritable traits so the owners can understand their dog’s health plans for the future. It also provides an app for dog owners to book an appointment and invite the Embark team to their homes to learn more about the test kit.
- Jul 2021Series B$75M
- Apr 2019Series A$12.9M
- Jul 2018Conventional Debt$1.5M
- Jul 2017Series A$4.5M
#4
Acquired · Austin, Texas · founded 2006 · 114 employees$80Mraised▾
Molecular diagnostics and genetics company advancing precision medicine in oncology. They are dedicated to improving patient outcomes through innovative molecular diagnostic solutions. They specialize in developing and commercializing cutting-edge testing kits and services for inherited genetic disorders and cancer. Their portfolio includes a range of AmplideX genetics assay kits for inherited disorders and QuantideX qPCR kits for precision oncology. They offer molecular quality controls and OEM services. They leverage enabling technologies, assay chemistries, and bioinformatics to drive product development. They provide genetic testing solutions, including carrier screening. They are committed to advancing cancer care with precision oncology solutions, supporting research with targeted detection of molecular mutations. They offer diagnostic tests to monitor chronic myeloid leukemia. They provide resources, publications, and disease information. They operate in EMEA, providing solutions to European customers in genetics and oncology.
- Sep 2019Grant (prize money)$182.4K
- Sep 2019Grant (prize money)$227.1K
- Sep 2019Grant (prize money)$229.5K
- Jun 2019Grant (prize money)—
#5
Acquired · Austin, Texas · founded 1996 · 120 employees$53.1Mraised▾
Endocare provides cancer diagnostic and therapeutic instruments. The company offers an integrated biplane ultrasound that helps physicians with precise color Doppler visualization for detection of the tumor. The company also offers surgical instruments for cryopreserving the cancer cells and software for planning the surgery.
- May 2007Series B$7M
- Oct 2006Series B$16M
- Mar 2005Series B$15.6M
- Series B$14.5M
#6
Early Stage · Austin, Texas · founded 1988 · 300 employees$10.5Mraised▾
Provider of RNA extraction reagents and products. The products of the company include RNA extraction kits and RNA isolation reagents, single cell-to-CT kit for qRT-PCR, DNA & RNA purification & analysis equipment, and many more.
- Mar 2010Grant (prize money)$1.2M
- Jul 2009Grant (prize money)$1.2M
- Jun 2009Grant (prize money)$1.2M
- Jun 2009Grant (prize money)$273.5K
#7
Public · Austin, Texas · founded 2009 · 28 employees$3.1Mraised▾
Genprex is a developer of therapeutics to treat cancer at the molecular level. It offers Oncoprex, the lead product candidate injected with erlotinib, is a novel, pan-kinase inhibitor that works to induce apoptosis in cancer cells and control cell signaling and inflammatory pathways to treat tumors and cancer metastases at the molecular level. The therapies are used for the treatment of non-small cell lung cancer.
- Jul 2020Grant (prize money)$2.6M
- May 2020Post IPO$2.5M
- Feb 2020Post IPO$17.5M
- Jan 2020Post IPO$8M
#8
Funding Raised · Austin, Texas · founded 2003$5Mraised▾
Streamlining preclinical research with innovative technology and solutions for enhanced results. They are dedicated to transforming preclinical research through their cloud-based platform, designed to standardize workflows, enhance data quality, and improve study reproducibility. From experimental design and electronic data capture to reporting and collaboration, they empower researchers and teams of all sizes to achieve cleaner, more reliable results. With a focus on scalability, usability, and advanced computing power, they provide tools that simplify complex processes while maintaining the highest standards of scientific rigor. Their Study Manager software supports study management, intelligent experimental design, automated electronic data capture, dynamic reporting tools, collaborative team support, and personal assistance with AI. They offer professional services and a help center, ensuring users can effectively utilize the platform for their research needs. The platform supports features like automated blinding, randomization, real-time alerts, and secure cloud storage.
- Mar 2016Grant (prize money)$2.2M
- Sep 2010Grant (prize money)$1.1M
- Jul 2009Grant (prize money)$134.4K
- Jun 2009Grant (prize money)$134.4K
#9
Deadpooled · Austin, Texas · founded 2015$5.6Mraised▾
PHDx offers a solution for detection of early prognosis of cardiovascular diseases in patients. The solution analyses patients genetic structure to provide reports about possible disorders like chronic lipid disorders, progressive inflammation, advancing insulin resistance, etc.
- Jul 2018Series A$5.6M
#10
Seed · Austin, Texas · founded 2002 · 2 employees$3.6Mraised▾
Provider of personalized supplement and diet recommendations based on biochemical analysis. The company performs a health assessment and collects the user's DNA (via a home kit) and analyzes the gene to provide information related to brain health, gut health, and hormone health. It provides personalized diet and supplements recommendations for users, using their genetic information.
- Jan 2018Seed$3.6M
#11
Seed · Austin, Texas · founded 2012$3Mraised▾
Developer of microRNA-targeted therapeutics to treat human obesity. The company develops microRNA-targeted therapeutics that enhance thermogenesis by turning fat-storing white adipocytes into fat-burning adipocytes. It also develops drug delivery approaches that target microRNA modulators to adipose tissue.
- Sep 2016Seed—
- Sep 2015Seed$3M
#12
Acqui-Hired · Austin, Texas · founded 2012$195Kraised▾
Provider of technology for genome sequencing, data management and computational analysis. The company provides its users the entire process from sample preparation to computational analysis and interpretation, to derive maximal value from genomic data.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Austin is moving
A read on the academic research around Bioinformatics in Austin — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 113 papers.
- The University of Texas at Austin81
- Austin Health19
- Austin College8
- Austin Community College3
- Austin Hospital2
- Gene1→3
- Epilepsy2
- DNA sequencing2
- Signal transduction2
- Kinase2
- Secretion1
- Disease1→4
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.